Free Design Audit Available - Click Here for Details

SetPoint Medical wins FDA breakthrough nod for nerve stim tech for multiple sclerosis

SetPoint Medical announced today that received FDA breakthrough device designation for its novel neuroimmune modulation platform.

Valencia, California–based SetPoint designed its nerve modulation technology for people with relapsing-remitting multiple sclerosis (RRMS). Breakthrough designation enables more communication and priority regulatory review with the FDA. Plus, it supports reimbursement and patient access upon approval.

This isn’t the first breakthrough nod for SetPoint’s technology. It picked up the designation in 2020 to treat rheumatoid arthritis (RA). The company continues evaluating the investigational platform in a pivotal clinical trial for the treatment of RA.

Sign up for Blog Updates